Type
Sell
Instrument
LALPATHLAB
Entry Price
₹1,880
Price@Trade
₹1,879.05
Target Price
₹1,800
Stop Price
Valid Till
Aug 3, 2020 3:20 AM
Margin
₹752,000 approx for 400 Qty
Status
Exited
Exit Price
₹1,852
Net P&L
+₹11,200 (+1.49%)
FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors
Find answers to all your questions on live LALPATHLAB message board: Is LALPATHLAB buy or sell? Should I buy LALPATHLAB shares? Why are LALPATHLAB shares falling? Should I invest in LALPATHLAB stock?
forum
LALPATHLAB Share Price Discussion
Dr. Lal Path Labs Ltd.
NSE: LALPATHLAB | BSE: 539524 | ISIN: INE600L01024 | Sector: Pharmaceuticals and health care
N
Reputation: 4,641 • Jul 7 9:36 AM
Outlook for diagnostics industry favourable for growth: Dr Lal PathLabs
The company said it served 1.94 crore patients and processed 4.77 crore samples
The company said it served 1.94 crore patients and processed 4.77 crore samples
The Economic Times
Like
Reply
NSE:LALPATHLAB price when posted: 1,720
Recent posts in LALPATHLAB
D
Reputation: 21,340 • Today 5:00 AM
Prabhudas Lilladher target on LALPATHLAB
Date: 03-Aug-20
Broker: Prabhudas Lilladher
Price @ Call: 1888.85
Target: 1006
Recommendation: SELL
Like
Reply
N
Reputation: 4,641 • Jul 31 9:56 AM
Dr Lal PathLabs Q1 results: Net profit declines 52% to Rs 28.4 crore
The company had posted a net profit of Rs 59.1 crore for the corresponding period of the previous fiscal, Dr Lal PathLabs said in a filing to BSE.
The company had posted a net profit of Rs 59.1 crore for the corresponding period of the previous fiscal, Dr Lal PathLabs said in a filing to BSE.
The Economic Times
Like
Reply
N
Reputation: 4,641 • Jul 31 8:43 AM
Dr Lal PathLabs Q1 profit falls 52% to Rs 28.4 crore
Its revenue was down 20.6% at Rs 266 crore against Rs 335.2 crore.
Its revenue was down 20.6% at Rs 266 crore against Rs 335.2 crore.
Moneycontrol
Like
Reply
N
Reputation: 4,641 • Jul 23 4:46 AM
Pick up these 5 pharma stocks in August: Sanjiv Bhasin
Pharma is in for profit booking for the next week or so, but August will again belong to most of the large cap pharma stocks.
Pharma is in for profit booking for the next week or so, but August will again belong to most of the large cap pharma stocks.
The Economic Times
Like
Reply
N
Reputation: 4,641 • Jul 15 7:38 AM
Dr Lal PathLabs shares hit fresh all-time high; analysts positive on firm's long term story
Despite the turmoil caused by COVID-19, the stock has been gaining significantly in the calendar year 2020 so far. The stock has gained 27 percent as of July 14 close on BSE against a 13 percent fall in benchmark Sensex.
Despite the turmoil caused by COVID-19, the stock has been gaining significantly in the calendar year 2020 so far. The stock has gained 27 percent as of July 14 close on BSE against a 13 percent fall in benchmark Sensex.
Moneycontrol
Like
Reply